Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 30 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
17 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
ChemoSensoryX Biosciences SA from Ottignies-Louvain-la-Neuve, company number BE0867817428, closed financial year 2025 with a result of € -1.4 million after tax. For that financial year ChemoSensoryX Biosciences SA recorded a gross margin of € -597,516 and equity of € -441,906. Compared with financial year 2024, the result moved from € -5,029 to € -1.4 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ -441,906
▼ € 1.1 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.4 million
▼ 26941 % more loss than in 2024
Profit after tax over the fiscal year.
€ 521,441
▼ 25% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.4 million.
People and assets in 2025
€ 506,243
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4,211
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 51,331
▲ € 51,119 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 67,248
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | - | € -2,585 | € -4,899 | € -597,516 | ▼ € 592,617 |
| Profit after taxes | € -466 | € -3,048 | € -5,029 | € -1,359,953 | ▼ € 1.4 million |
| Equity | € 11,752 | € 8,705 | € 690,524 | € -441,906 | ▼ € 1.1 million |
| Total debts | € 348 | € 0 | € 212 | € 1,968,579 | ▲ € 2 million |
| Cash | € 12,100 | € 3,564 | € 690,736 | € 521,441 | ▼ 25% |
| Retained profit | € -49,748 | € -52,795 | € -57,824 | € -1,417,777 | ▼ € 1.4 million |
| Balance sheet total | € 12,100 | € 8,705 | € 690,736 | € 1,526,673 | ▲ 121% |
Key figures of ChemoSensoryX Biosciences SA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ChemoSensoryX Biosciences SA?
What happened at ChemoSensoryX Biosciences SA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Guillaume Tardif stepped down as director. NBB
- Bernard Boulin stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.4 million. Source: NBB ↗
- ACADEMIC MEDICAL INTERDISCIPLINARY RESEARCH FOUNDATION ASBL (A.M.I.R.) stepped down as director. NBB
- Guillaume Tardif became a director. NBB
- Bernard Boulin became a director. NBB
- COVORIM BV stepped down as director. NBB
- ASSOCIATION RECHERCHE BIOMEDICALE ET DIAGNOSTIC (A.R.B.D.) stepped down as director. NBB
In short
From € 466 loss in 2022 to € 1.4 million loss in 2025.
Paid € 2 in corporate taxes since 2022.
A new publication or filing at ChemoSensoryX Biosciences SA? We notify you, reason included.
Follow ChemoSensoryX Biosciences SADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of IMMO BVDV comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ChemoSensoryX Biosciences SAThe shares are held by IMMO BVDV (99.9%).
Directors
According to the 2025 annual accounts
ACADEMIC MEDICAL INTERDISCIPLINARY RESEARCH FOUNDATION ASBL (A.M.I.R.)
Director · represented by Joelle Dumont
Also active at: CHEMCOM
since 2024 · until 2025
Guillaume Tardif
Director
since 2025 · until 2031
Bernard Boulin
Director
since 2025 · until 2031
Director · represented by Benedikt Van Der Vorst
Also active at: CHEMCOM, Allegro Investment Fund
since 2024 · until 2025
ASSOCIATION RECHERCHE BIOMEDICALE ET DIAGNOSTIC (A.R.B.D.)
Director · represented by Gilbert Vassart
since 2024 · until 2025
Bernard Delwart
Director
since 2024 · until 2025
since 2024 · until 2025
Shareholders
99.9%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Avenue Jean Monnet 1
1348 Ottignies-Louvain-la-Neuve
Drève Richelle 161P box 4
1410 Waterloo
Active since 13 October 2004
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 17 companies are registered at this address.
All companies at this address →BETA Systems Software
€ 169,402 gross margin · 2025
AIR VISION
€ 71,505 gross margin · 2025
HEXION RESEARCH BELGIUM SA
€ 2.5 million gross margin · 2025
FEMAG
€ -13,629 gross margin · 2025
CHEMIUM
€ 277,473 gross margin · 2025
+12 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0867.817.428
- VAT number
- BE 0867.817.428
- Registered office
- Avenue Jean Monnet 1, 1348 Ottignies-Louvain-la-Neuve
- Names & denominations
- ChemoSensoryX Biosciences SA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 October 2004
- Peppol
- Active · Active since 25 Nov 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Bemiddeling in verband met exploitatie van en handel in onroerend goed